Authors: | Rietschel, P.; Chapman, P. B. |
Article Title: | Immunotherapy of melanoma |
Abstract: | Melanoma has been widely studied as a target for immunotherapy because it has been considered more susceptible to immune attack than other tumors and because of the relative ease with which melanoma cells can be adapted to in vitro culture. The availability of hundreds of melanoma cell lines for study has led to the identification of tumor antigens and the development of monoclonal antibodies and T cells against these antigens, revolutionizing the understanding of how the immune system sees and reacts to cancer. This article reviews the recent clinical results of trials exploring different immunotherapy strategies against melanoma. © 2006 Elsevier Inc. All rights reserved. |
Keywords: | cancer survival; unclassified drug; clinical trial; fatigue; review; diarrhea; liver dysfunction; adjuvant therapy; bcg vaccine; canvaxin; dendritic cell vaccine; interleukin 2; melanoma; nausea; myalgia; granulocyte macrophage colony stimulating factor; monoclonal antibody; arthralgia; chill; fever; hypotension; cytokines; immunotherapy; recombinant gamma interferon; cancer vaccines; sepsis; dna vaccine; headache; heart arrhythmia; alpha2a interferon; melacine; trastuzumab; cytotoxic t lymphocyte antigen 4; antibodies, neoplasm; immunotherapy, adoptive; ganglioside gm2; cell transfer; night sweat; ganglioside; melanoma vaccine; recombinant alpha interferon; emd 273063; ganglioside gd2 vaccine; km 871; peptide antigen vaccine |
Journal Title: | Hematology/Oncology Clinics of North America |
Volume: | 20 |
Issue: | 3 |
ISSN: | 0889-8588 |
Publisher: | Elsevier Inc. |
Date Published: | 2006-06-01 |
Start Page: | 751 |
End Page: | 766 |
Language: | English |
DOI: | 10.1016/j.hoc.2006.02.005 |
PUBMED: | 16762733 |
PROVIDER: | scopus |
DOI/URL: | |
Notes: | --- - "Cited By (since 1996): 6" - "Export Date: 4 June 2012" - "CODEN: HCNAE" - "Source: Scopus" |